Interview: CellCentric Prostate Cancer Drug Promises Much
The Cambridge-based company's CEO Will West tells Scrip that CCS1477 has shown a lot of potential for patients with late-stage prostate cancer who are resistant to second-line anti-androgen drugs like Zytiga and Xtandi and the $26m it has just raised will help fund development of the epigenetic therapy up to Phase IIb.
You may also be interested in...
Private Company Edition: Celgene's former top deal-maker George Golumbeski is now a life science business consultant and venture partner at ARCH. Also, a VC investment surge portends another big year for biopharma, including $85m for Ansun and $66m for FogPharma.
Takeda has licensed an epigenetic programme from UK firm CellCentric with a primary focus on cancer. The deal, which includes an upfront payment, preclinical and clinical milestones, and royalties on any future products, could be worth more than $200 million to CellCentric over the course of the agreement.
The French biotech has presented positive Phase II data on lacutamab in mycosis fungoides at the EORTC-CLTG meeting in Madrid which looks to have de-risked the asset.